NEW YORK,
Sept. 27,
2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.
(NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in
the development of targeted radiotherapies, today details an
abstract accepted for poster presentation at the upcoming Society
of Immunotherapy of Cancer (SITC) 38th Annual Meeting,
which will be held in San Diego,
November 3-5, 2023.
Details of the SITC poster
presentation:
Abstract Title: Preclinical
evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate
targeting myeloid-derived suppressor cells
Abstract Number: 1166
Session: November 4,
9:00 AM – 8:30
PM PT, Exhibit Halls A and B1
About Actinium
Actinium develops targeted radiotherapies to
meaningfully improve survival for people who have failed existing
oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA),
an induction and conditioning agent prior to bone marrow
transplant, and Actimab-A (National Cancer Institute CRADA pivotal
development path), a therapeutic, have demonstrated potential to
extend survival outcomes for people with relapsed and refractory
acute myeloid leukemia. Actinium plans to advance Iomab-B for
other blood cancers and next generation conditioning candidate
Iomab-ACT to improve cell and gene therapy outcomes. Actinium's
technology platform is the basis for collaborations
with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem
Life Sciences for HER3 solid tumors, and EpicentRx for its CD47
targeting agent, and several internal programs in solid tumors.
Actinium holds more than 200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or
other "forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-highlights-abstract-accepted-for-poster-presentation-at-the-sitc-38th-annual-meeting-301939957.html
SOURCE Actinium Pharmaceuticals, Inc.